Benzinga | Oct 13, 2021 01:38PM EDT

Bristol Myers Squibb Announces Up to Five Years of Data from Long-Term DAYBREAK Study Reinforcing Efficacy and Safety Profile of Zeposia in Patients with Relapsing Forms of Multiple Sclerosis



Treatment with Zeposia demonstrated a low annualized relapse rate (ARR) of 0.103 and more than 70% of patients were relapse-free at four years

Safety was consistent with prior findings and the established safety profile of Zeposia in up to 5 years of follow-up